Advertisement

Supportive Care in Cancer

, Volume 19, Issue 3, pp 435–438 | Cite as

The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study

  • Sebastiano MercadanteEmail author
  • Patrizia Ferrera
  • Edoardo Arcuri
Short Communication

Abstract

Background

Data on the treatment of beakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking. Whether methadone produces tolerance to other opioids, other opioids should be less effective when administered as a BTcP medication.

Aim

The aim of this preliminary study was to assess the efficacy of fentanyl buccal tablets (FBT) for the treatment of BTcP in patients who receive methadone as a background analgesic.

Patients and methods

A prospective study was carried out for a period of 1 year in a consecutive sample of 13 advanced cancer patients admitted to an acute pain relief and palliative care unit—patients who were receiving stable doses of oral methadone for their background analgesia. The dose of FBT was 100 μg for patients who were receiving 12 mg of oral methadone. For higher doses of methadone, proportional doses of FBT were given. For each episode, trained nurses collected changes in pain intensity (on numerical scale 0–10) and emerging problems when called for pain increases considered to be severe in intensity by patients) (T0) and 15 min after FBT administration (T15).

Results

The mean age was 58.1 (SD 9.9), and nine patients were males. Sixty-four events were treated with FBT (4.9 ± 3.1 for each patient, on average). Patients were receiving mean doses of oral methadone of 68 mg (range 15–240). In the majority of events, a decrease in pain intensity >33% and >50% was observed (n = 20 and n = 26, respectively), 15 min after the administration of FBT. Data on ten episodes were unavailable. Nine events were unsuccessfully treated. In all the patients, the level of adverse effects after FBT administration was mild and undistinguishable from that associated with basal opioid analgesia.

Conclusion

FBT was effective as breakthrough pain medication in patients receiving methadone for their background analgesia, confirming that this group of patients are not inevitably resistant to other opioids.

Keywords

Breakthrough pain Methadone therapy Fentanyl buccal tables Cancer pain 

References

  1. 1.
    Bruera E, Pereira J, Watanabe S et al (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRefGoogle Scholar
  2. 2.
    Bruera E, Palmer JL, Bosnjak S et al (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22:185–192PubMedCrossRefGoogle Scholar
  3. 3.
    Darwish M, Robertson P, Tracewell W et al (2006) Comparative availability of the novel fentanyl effervescent buccal tablet formulation: an open label crossover study. J Pain 7(4 suppl 1):35Google Scholar
  4. 4.
    Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338PubMedCrossRefGoogle Scholar
  5. 5.
    Eugenio KR (2004) Profound morphine tolerance following high-dose methadone therapy. J Pain Palliat Care Pharm 18:47–54Google Scholar
  6. 6.
    Fisher K, Stiles C, Hagen NA (2004) Characterization of the early pharmacologic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 28:619–625PubMedCrossRefGoogle Scholar
  7. 7.
    Hagen NA, Fisher K, Stiles C (2007) Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med 10:331–337PubMedCrossRefGoogle Scholar
  8. 8.
    Hagen NA, Fisher K, Victorino C, Farrar JT (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47–55PubMedCrossRefGoogle Scholar
  9. 9.
    Hanks GW, De Conno F, Cherny N et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593PubMedCrossRefGoogle Scholar
  10. 10.
    Lawlor P, Turner K, Hanson J, Bruera E (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82:1167–1173PubMedCrossRefGoogle Scholar
  11. 11.
    Mercadante S, Portenoy RK (2001) Opioid poorly responsive cancer pain. Part 2. Basic mechanisms that could shift dose–response for analgesia. J Pain Symptom Manage 21:255–264PubMedCrossRefGoogle Scholar
  12. 12.
    Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304–315PubMedCrossRefGoogle Scholar
  13. 13.
    Mercadante S, Porzio G, Ferrera P et al (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12:1040–1046PubMedCrossRefGoogle Scholar
  14. 14.
    Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A (2004) Safety and effectiveness of intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 27:352–359PubMedCrossRefGoogle Scholar
  15. 15.
    Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S (2008) Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 35:307–313PubMedGoogle Scholar
  16. 16.
    Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G (2007) Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 96:1828–1833PubMedCrossRefGoogle Scholar
  17. 17.
    Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S (2009) Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37:632–641PubMedCrossRefGoogle Scholar
  18. 18.
    Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A (2010) The use of opioids for breakthrough pain in an acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 26:306–309PubMedCrossRefGoogle Scholar
  19. 19.
    Moryl N, Santiago-Palma J, Kornick C et al (2002) Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 96:325–328PubMedCrossRefGoogle Scholar
  20. 20.
    Portenoy RK, Taylor D, Messina J, Tremmel L (2006) A randomized, placebo-controlled study of fentanyl buccal tablets for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 22:805–811PubMedCrossRefGoogle Scholar
  21. 21.
    Slatkin N, Messina J, Segal T (2007) Fentanyl buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 5:327–334PubMedGoogle Scholar
  22. 22.
    Walter P, Palla S, Pei B et al (2008) Switching from methadone to different opioid: what is the equianalgesic ratio? J Palliat Med 11:1103–1108CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sebastiano Mercadante
    • 1
    Email author
  • Patrizia Ferrera
    • 1
  • Edoardo Arcuri
    • 2
  1. 1.Anesthesia and Intensive Care Unit Pain Relief and Palliative Care UnitLa Maddalena Cancer CenterPalermoItaly
  2. 2.Sacro Cuore HospiceRomeItaly

Personalised recommendations